EP5 – Antineoplastic effect of vandetanib vs lenvatinib in primary anaplastic thyroid cancer cells, obtained from fine needle aspiration, or biopsy


    Antonelli, Alessandro1, Poupak Fallahi1, Ferrari, Silvia Martina1, La Motta, Concettina2, Elia, Giusy1, Bonatti, Andrea1, Materazzi, Gabriele3, Galleri, Davide3, Miccoli, Paolo3
    1 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
    2 Department of Pharmacy, University of Pisa, Pisa, Italy
    3 Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy

     In vitro chemosensitivity tests in “primary ATC cell” (ANA) cultures from each patient to different drugs could permit to increase the effectiveness of the treatment, avoiding the administration of inactive potentially dangerous therapies. To study the antineoplastic effect of vandetanib and lenvatinib in primary cells from anaplastic thyroid cancer (pATC) obtained from fine needle aspiration (FNA-pATC), in comparison with biopsy (biop-pATC).

    Methods: The antiproliferative effect was tested in ATC-cells obtained both from biop-pATC, such as from FNA-pATC, in 6 patients. The concentrations of vandetanib, and lenvatinib used in the in vitro experiments were 1 nM, 30 nM, 100 nM, 300 nM, 1000 nM.

    Results: An antiproliferative effect of lenvatinib (by WST-1 assay) was observed in FNA-pATC or biop-pATC, and at a slight level with vandetanib. Both vandetanib and lenvatinib, increased significantly the percentage of apoptotic cells in FNA-pATCs or biop-pATCs, dose-dependently. No significant difference was observed in antineoplastic effect of vandetanib or lenvatinib, among the tested ATC cells from FNA or biopsy.

    Discussion & Conclusion: In conclusion: 1) vandetanib and lenvatinib are effective in reducing cell growth, increasing apoptosis in ATC; 2) primary cells obtained by FNA-ANA have a sensitivity to TKIs agents quite similar to that observed in primary cells from biopsy; 3) the possibility to test sensitivity to different TKIs in each patient will be able to increase the efficacy of treatments, avoiding the administration of ineffective and potentially dangerous drugs.


Leave a Reply

  • Upcoming Events


    World Congress on Thyroid Cancer 3.5
    June 20 – 22, 2019
    Rome, Italy

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts


  • WCTC3.5 Steering Committee:


    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD